Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devalingam Mahalingam

Showing results (11-20 of 103) with videos related to

Pageof 11
Sort By:
Drug Design, Development and Therapy|November 19, 2009
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinibRonan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, et al.
Cancer Treatment Reviews|January 2, 2009
TRAIL receptor signalling and modulation: Are we on the right TRAIL?Devalingam Mahalingam, Eva Szegezdi, Maccon Keane, et al.
Targeted Oncology|April 22, 2009
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitorsKevin Kelly, Ronan Swords, Devalingam Mahalingam, et al.
Targeted Oncology|May 5, 2011
Clinical activity of mammalian target of rapamycin inhibitors in solid tumorsYesid Alvarado, Monica M Mita, Sushma Vemulapalli, et al.
Targeted Oncology|April 22, 2009
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agentsKamalesh Sankhala, Alain Mita, Kevin Kelly, et al.
Journal of Gastrointestinal Cancer|April 23, 2017
Left Versus Right: Does Location Matter for Refractory Metastatic Colorectal Cancer Patients in Phase 1 Clinical Trials?Sukeshi Patel Arora, Norma S Ketchum, Joel Michalek, et al.
Future Oncology (London, England)|April 21, 2009
Targeting the mTOR pathway using deforolimus in cancer therapyDevalingam Mahalingam, Kamalesh Sankhala, Alain Mita, et al.
Journal of Gastrointestinal Oncology|March 11, 2017
Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: a single institution experienceChristos Fountzilas, Katherine Chang, Brian Hernandez, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2009
Cdc7 kinase - a new target for drug developmentRonan Swords, Devalingam Mahalingam, Michael O'Dwyer, et al.
Clinical Pharmacology in Drug Development|May 10, 2025
Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced MalignanciesYingxue Chen, Renli Teng, Attila Szanto, et al.
Pageof 11

Showing results (11-20 of 103) with videos related to

Sort By:
Pageof 11
Drug Design, Development and Therapy|November 19, 2009
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinibRonan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, et al.
Cancer Treatment Reviews|January 2, 2009
TRAIL receptor signalling and modulation: Are we on the right TRAIL?Devalingam Mahalingam, Eva Szegezdi, Maccon Keane, et al.
Targeted Oncology|April 22, 2009
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitorsKevin Kelly, Ronan Swords, Devalingam Mahalingam, et al.
Targeted Oncology|May 5, 2011
Clinical activity of mammalian target of rapamycin inhibitors in solid tumorsYesid Alvarado, Monica M Mita, Sushma Vemulapalli, et al.
Targeted Oncology|April 22, 2009
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agentsKamalesh Sankhala, Alain Mita, Kevin Kelly, et al.
Journal of Gastrointestinal Cancer|April 23, 2017
Left Versus Right: Does Location Matter for Refractory Metastatic Colorectal Cancer Patients in Phase 1 Clinical Trials?Sukeshi Patel Arora, Norma S Ketchum, Joel Michalek, et al.
Future Oncology (London, England)|April 21, 2009
Targeting the mTOR pathway using deforolimus in cancer therapyDevalingam Mahalingam, Kamalesh Sankhala, Alain Mita, et al.
Journal of Gastrointestinal Oncology|March 11, 2017
Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: a single institution experienceChristos Fountzilas, Katherine Chang, Brian Hernandez, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2009
Cdc7 kinase - a new target for drug developmentRonan Swords, Devalingam Mahalingam, Michael O'Dwyer, et al.
Clinical Pharmacology in Drug Development|May 10, 2025
Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced MalignanciesYingxue Chen, Renli Teng, Attila Szanto, et al.
Pageof 11